Intra-Cellular Therapies Inc(ITCI) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States. The company is developing its lead drug candidate, CAPLYTA for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases. It is also developing ITI-002 that inhibits the enzyme phosphodiesterase type 1; ITI-214 for Parkinson's disease; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.

Current Price

$33.43

RSI

41.858

Beta:

1.339768

February 25, 2021
-68.3M

20447.193 %
209.597 %
-49.543 %
-42.074 %

$22,812,979
$60,613
$0
$245,837
$330,702
$91,364
37537.106 %
100.000 %
-Infinity %
-34.521 %
261.961 %

$-226,992,150
$-147,720,578
$-155,125,811
$-98,834,265
$-115,360,595
$-104,791,541
-34.923 %
5.013 %
-36.288 %
16.721 %
-9.162 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.